Switzerland Pharmaceuticals and Healthcare Report Q1 2016

71 pages report Published in
Pharmaceuticals
Publisher: Business Monitor International

arrowFor This Report

BMI View: Roche’s restructuring efforts within its manufacturing network are indicative of deep pipeline
shifts. Tailored manufacturing capability will support the company’s established biosimilar defence strategy
as it prepares itself for erosion of key product revenues to begin in 2018. As part of an industry-wide trend,
we expect to see further traditional small-molecule plants being decommissioned and investment being put
into increasing in-house biologics capabilities.
Headline Expenditure Projections
? Pharmaceuticals: CHF7.06bn (USD7.71bn) in 2014 to CHF7.07bn (USD7.27bn) in 2015; +0.10% in
local currency terms and -5.8% in US dollar terms. Forecast stayed flat compared to last quarter.
? Healthcare: CHF70.49bn (USD77.02bn) in 2014 to CHF71.88bn (USD73.89bn) in 2015; +2.0% growth
in local currency terms and -4.1% in US dollar terms. Forecast revised slightly downwards from last
quarter.

Table of Contents

BMI Industry View 7
Table: Headline Pharmaceuticals & Healthcare Forecasts (2013-2019) 7
SWOT 9
Industry Forecast 11
Pharmaceutical Market Forecast 11
Table: Pharmaceutical Sales, Historical Data And Forecasts (Switzerland 2011-2019) 13
Healthcare Market Forecast 13
Table: Healthcare Expenditure Trends, Historical Data And Forecasts (Switzerland 2011-2019) 15
Table: Government Healthcare Expenditure Trends, Historical Data And Forecasts (Switzerland 2011-2019) 16
Table: Private Healthcare Expenditure Trends, Historical Data And Forecasts (Switzerland 2011-2019) 16
Prescription Drug Market Forecast 17
Table: Prescription Drug Market Indicators, Historical Data And Forecasts (Switzerland 2011-2019) 18
Patented Drug Market Forecast 19
Table: Patented Drug Market Indicators, Historical Data And Forecasts (Switzerland 2011-2019) 20
Generic Drug Market Forecast 21
Table: Generic Drug Market Indicators, Historical Data And Forecasts (Switzerland 2011-2019) 22
OTC Medicine Forecast 23
Table: Over-The-Counter (OTC) Medicine Market Indicators, Historical Data And Forecasts (Switzerland 2011-2019) 24
Pharmaceutical Trade Forecast 25
Table: Pharmaceutical Trade Data And Forecasts (Switzerland 2013-2019) 26
Table: Pharmaceutical Trade Data And Forecasts local currency (Switzerland 2013-2019) 26
Industry Risk/Reward Index 27
Western Europe Risk/Reward Index 27
Switzerland Risk/Reward Index 33
Rewards 33
Risks 33
Regulatory Review 35
Intellectual Property Issues 35
Pricing Regime 35
Reimbursement Regime 36
Market Overview 38
Healthcare Sector 39
Table: 2013 & 2014: Health Insurance Premiums 40
Table: Healthcare Resources (Switzerland 2009-2014) 41
Table: Healthcare Personnel (Switzerland 2009-2014) 41
Table: Healthcare Activity (Switzerland 2009-2014) 42
Research And Development 42
Clinical Trials 43
Epidemiology 44
Competitive Landscape 46
Research-Based Industry 46
Table: Table: Multinational Market Activity 47
Drugmakers 48
Retail 48
Company Profile 50
Novartis 50
Roche 54
GlaxoSmithKline 58
Demographic Forecast 60
Table: Population Headline Indicators (Switzerland 1990-2025) 61
Table: Key Population Ratios (Switzerland 1990-2025) 61
Table: Urban/Rural Population & Life Expectancy (Switzerland 1990-2025) 62
Table: Population By Age Group (Switzerland 1990-2025) 62
Table: Population By Age Group % (Switzerland 1990-2025) 63
Glossary 65
Methodology 67
Pharmaceutical Expenditure Forecast Model 67
Healthcare Expenditure Forecast Model 67
Notes On Methodology 68
Risk/Reward Index Methodology 69
Index Overview 70
Table: Pharmaceutical Risk/Reward Index Indicators 70
Indicator Weightings 71

List of Tables

Table: Headline Pharmaceuticals & Healthcare Forecasts (2013-2019)
Table: Pharmaceutical Sales, Historical Data And Forecasts (Switzerland 2011-2019)
Table: Healthcare Expenditure Trends, Historical Data And Forecasts (Switzerland 2011-2019)
Table: Government Healthcare Expenditure Trends, Historical Data And Forecasts (Switzerland 2011-2019)
Table: Private Healthcare Expenditure Trends, Historical Data And Forecasts (Switzerland 2011-2019)
Table: Prescription Drug Market Indicators, Historical Data And Forecasts (Switzerland 2011-2019)
Table: Patented Drug Market Indicators, Historical Data And Forecasts (Switzerland 2011-2019)
Table: Generic Drug Market Indicators, Historical Data And Forecasts (Switzerland 2011-2019)
Table: Over-The-Counter (OTC) Medicine Market Indicators, Historical Data And Forecasts (Switzerland 2011-2019)
Table: Pharmaceutical Trade Data And Forecasts (Switzerland 2013-2019)
Table: Pharmaceutical Trade Data And Forecasts local currency (Switzerland 2013-2019)
Table: 2013 & 2014: Health Insurance Premiums
Table: Healthcare Resources (Switzerland 2009-2014)
Table: Healthcare Personnel (Switzerland 2009-2014)
Table: Healthcare Activity (Switzerland 2009-2014)
Table: Table: Multinational Market Activity
Table: Population Headline Indicators (Switzerland 1990-2025)
Table: Key Population Ratios (Switzerland 1990-2025)
Table: Urban/Rural Population & Life Expectancy (Switzerland 1990-2025)
Table: Population By Age Group (Switzerland 1990-2025)
Table: Population By Age Group % (Switzerland 1990-2025)
Table: Pharmaceutical Risk/Reward Index Indicators

Related Reports

  • Switzerland Pharmaceuticals and Healthcare Report Q4 2014BMI View: Most of Switzerland's demographic and economic indicators are favourable towards increased pharmaceutical and healthcare spending. The proportion of the pensionable population is high and growing, and this will translate into greater demand for drugs. Furthermore, the country's highly developed infrastructure means that access to healthcare is easy, further supporting the consumption of medicines. Headline Expenditure Projections ? Pharmaceuticals: CHF7.06bn (USD7.68bn) in […]
  • Switzerland Pharmaceuticals and Healthcare Report Q3 2015BMI View: The preference for patented drugs over low-value generic medicines by patients and prescribers in Switzerland will drive the government to continue to enforce measures that restrict growth in innovative medicine sales - particularly as the ageing population will boost the demand for long-term medicines. This will include price cuts on patented medicines as well as a push towards the greater promotion of lowervalue generic medicines. Headline Expenditure Projections ? […]
  • Switzerland Pharmaceuticals and Healthcare Report Q4 2015BMI View: The expected growth of Switzerland's ageing population over the next 50 years will have an unprecedented impact on the demand for healthcare. This has the potential to provide private healthcare providers with significant business expansion and revenue-earning opportunities, especially as the government tries to provide healthcare services while containing costs. Headline Expenditure Projections ? Pharmaceuticals: CHF7.06bn (USD7.71bn) in 2014 to CHF7.07bn (USD7.26bn) in […]
  • Malaysia Pharmaceuticals and Healthcare Report Q3 2014BMI View: We remain generally optimistic towards Malaysia's commitment to provide better quality and access to healthcare, as the government plans to expand and upgrade its hospital network. However, we have downgraded Malaysia's pharmaceutical sales forecast due to a slowdown in pharmaceutical trade in 2013. The country's slower economic growth in 2014, coupled with the fact that investment in the pharmaceuticals sector will take longer than expected to bring returns, are downside […]
  • Sudan and South Sudan Pharmaceuticals and Healthcare Report Q3 2015BMI View: Due to the lack of production capacity among domestic companies, the majority of pharmaceuticals in Sudan and South Sudan will remain sourced from abroad. Over the long-term, domestic manufacturers will increase their market share, with the government placing an increasing emphasis on achieving self-sufficiency in terms of pharmaceutical production. Headline Expenditure Projections ? Pharmaceuticals: SDG2.35bn (USD402mn) in 2014 to SDG2.65bn (USD433mn) in 2015; +12.9% […]

arrowStay In Touch

RSS